Paper Details
- Home
- Paper Details
Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.
Author: AraeHirotaka, FujitaJiro, KamiKaoru, MaedaSaori, MiyagiKyoko, MoromiMakiko, NakamuraHideta, NakamuraKatsunori, TasatoDaisuke, TateyamaMasao, UeharaHitoshi
Original Abstract of the Article :
Objective Recently, tenofovir disoproxil fumatate (TDF)-related side effects, such as renal nephrotoxicity and reduction of bone mineral density, have been reported. Consequently, increased switching from fixed-dose tablet TDF and emtricitabine (TDF/FTC) to abacavir and lamivudine (ABC/3TC) has occu...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216139/
データ提供:米国国立医学図書館(NLM)
Evaluation of Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine
The development of effective antiretroviral therapies has revolutionized the treatment of HIV infection, significantly improving the lives of millions of people. This study examines the impact of switching from one antiretroviral regimen to another, focusing on the potential effects on lipid levels. This research, like a skilled navigator charting a new course through a vast ocean, explores the uncharted territories of antiretroviral therapy.
Switching Regimens: A Potential for Lipid Elevation
This study, like a ship encountering a hidden reef, reveals a potential complication associated with switching from tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) to abacavir (ABC)/lamivudine (3TC). The study found that switching regimens led to significant increases in low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol (TC) levels. This finding highlights the importance of monitoring lipid levels in patients undergoing antiretroviral regimen changes.
Health Implications and Applications
This study, like a warning sign in the desert, underscores the need for careful monitoring of lipid levels in patients undergoing antiretroviral regimen changes. Clinicians should be aware of the potential for lipid elevation associated with switching from TDF/FTC to ABC/3TC and implement appropriate monitoring and management strategies to minimize cardiovascular risks.
Dr. Camel's Conclusion
This study, like a compass guiding a traveler through the desert, provides valuable insights into the potential lipid-related side effects associated with switching antiretroviral regimens. Careful monitoring and management are crucial to ensure the long-term health and well-being of patients receiving antiretroviral therapy.
Date :
- Date Completed 2017-02-06
- Date Revised 2018-12-02
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.